Brief: Arch Biopartners Announces Issuance Of U.S. Patent For Dipeptidase-1 Inhibitor Drug
04/12/2019 14:15
Dec 4 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES ISSUANCE OF U.S. PATENT FOR
DIPEPTIDASE-1 INHIBITOR DRUG FOR USE IN ACUTE KIDNEY INJURY
Source text for Eikon: ID:nGNX2Lf24c
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide